Clinical Trial Update: Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma [Phase 2]

View source ↗

Summary

A Phase 2 trial of Combivent CFC metered-dose inhaler for moderate to severe asthma has completed. The study was sponsored by Boehringer Ingelheim.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Combivent (ipratropium bromide and albuterol)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Asthma | Phase 2 | Status: COMPLETED